At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 676 enrolled
Drug / intervention
AIN457 300 mg +2 moredrug
Likely dose
AIN457 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
In Brief
A Phase 3 clinical trial evaluating AIN457 300 mg, ustekinumab 45/90 mg, and 1 other intervention for Chronic Plaque Type Psoriasis. Completed, enrolled 676 participants across 137 sites in 24 countries.
Detailed Summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Type Psoriasis
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Portugal, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedMar 2014
Primary CompletionJun 2016
TodayJul 2026
First PostedMar 3, 2014
Enrollment StartFeb 26, 2014
Primary CompletionJun 29, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.3 years ago
Interventions
AIN457 300 mgdrug
ustekinumab 45/90 mgdrug
placebo secukinumabdrug
Placebo